ETHNOPHARMACOLOGICAL RELEVANCE: Sphagneticola trilobata was traditionally used to alleviate wounds using topical plant preparations. The precise mechanism of the plant responsible for its wound healing effect are still unclear. Although the plant was reported to be cytotoxic, there is a lack of reported data regarding its cytotoxic impact on skin cancer. AIM OF THE STUDY: To in-depth investigate wound healing and cytotoxic effects of the plant extracts and its fractions by using different assays. MATERIALS AND METHODS: In vitro scratch assay and in vivo full-thickness wound model were performed to evaluate the plant's wound healing activity. Enzyme-linked immunosorbent assay kits were employed to assess key skin parameters levels. The cytotoxicity was evaluated using in vitro Western Standard Time assay against skin carcinoma cells. RESULTS: Sphagneticola trilobata improved the wound closure percentage in both in vitro scratch assay and in vivo model by modulating inflammation, as evidenced by a reduction in tumor necrosis factor and mitogen activated protein kinase levels, and enhancing proliferation via elevating collagen, smooth muscle actin, and forkhead protein. The total extract's efficacy surpassed the effectiveness of reference ointment. The non-polar fraction outperformed the polar one in accelerating wound closure and improving the tested skin parameters levels. Trilobolide-6-O-isobutyrate displayed the best docking scores for the selected target receptors. Moreover, the non-polar fraction demonstrated the most powerful cytotoxic effect against skin cancer cells. A specific compound mixture (kaurenoic acid/grandiflorenic acid, 1 and 2) within this fraction exhibited stronger cytotoxicity. CONCLUSIONS: Sphagneticola trilobata can be considered as a promising therapeutic agent in relieving wounds and combating skin cancer cell lines.